Yilmaz, B.; Ruckstuhl, L.; Müllhaupt, B.; Magenta, L.; Kuster, M.H.; Clerc, O.; Torgler, R.; Semmo, N.
Pilot Sub-Study of the Effect of Hepatitis C Cure by Glecaprevir/Pibrentasvir on the Gut Microbiome of Patients with Chronic Hepatitis C Genotypes 1 to 6 in the Mythen Study. Pharmaceuticals 2021, 14, 931.
https://doi.org/10.3390/ph14090931
AMA Style
Yilmaz B, Ruckstuhl L, Müllhaupt B, Magenta L, Kuster MH, Clerc O, Torgler R, Semmo N.
Pilot Sub-Study of the Effect of Hepatitis C Cure by Glecaprevir/Pibrentasvir on the Gut Microbiome of Patients with Chronic Hepatitis C Genotypes 1 to 6 in the Mythen Study. Pharmaceuticals. 2021; 14(9):931.
https://doi.org/10.3390/ph14090931
Chicago/Turabian Style
Yilmaz, Bahtiyar, Lisa Ruckstuhl, Beat Müllhaupt, Lorenzo Magenta, Melanie Harrer Kuster, Olivier Clerc, Ralph Torgler, and Nasser Semmo.
2021. "Pilot Sub-Study of the Effect of Hepatitis C Cure by Glecaprevir/Pibrentasvir on the Gut Microbiome of Patients with Chronic Hepatitis C Genotypes 1 to 6 in the Mythen Study" Pharmaceuticals 14, no. 9: 931.
https://doi.org/10.3390/ph14090931
APA Style
Yilmaz, B., Ruckstuhl, L., Müllhaupt, B., Magenta, L., Kuster, M. H., Clerc, O., Torgler, R., & Semmo, N.
(2021). Pilot Sub-Study of the Effect of Hepatitis C Cure by Glecaprevir/Pibrentasvir on the Gut Microbiome of Patients with Chronic Hepatitis C Genotypes 1 to 6 in the Mythen Study. Pharmaceuticals, 14(9), 931.
https://doi.org/10.3390/ph14090931
